Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline as a Preventive Treatment for Chronic Migraine
2021-005579-38Phase 2Completed
- Sponsor
- Aarhus University Hospital
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cabergoline in migraine, sponsored by Aarhus University Hospital. Primary endpoint: Reduction in number of days with headache. Started Nov 2021; status: completed.
02
Drugs
cabergoline
03
Conditions
migraine
Beyond the preview
Go deeper on 2021-005579-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005579-38.